Aeglea BioTherapeutics Investor Presentation Deck

MOA Intestinal epithelium Blood Vessel Spyre portfolio addresses the diverse pathophysiology of IBD Blockade of a437 prevents circulating T cells from entering inflammatory gut tissues Cell Cytotoxicity and Tissue Lesion SPY001 a437 0000000 SPYRE T-cell trafficking MADCAM1 Neutralization of TL1A suppresses inflammation within gut tissue and blocks immune cell activation SPY002 ➡ TL1A DR3 Colonic Fibrosis Inflammatory cascade Neutralization of IL-23 inhibits cascade of various proinflammatory cytokines IL-23 SPY003 IL-23R ¿di Th17 maturation Inflammatory cascade Sypre is a pioneer in developing potential best-in-class mAbs against three top targets with the goal of enabling superior combinations for IBD 29

View entire presentation